Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model
Ifeanyi K. Uche, Natalie W. Fowlkes, Luan D. Vu, Tatiane Terumi Negrão Watanabe, Mariano Carossino, Rafiq Nabi, Fábio Del Piero, Jared S. Rudd, Konstantin G. Kousoulas, Paul J. F. Rider
Abstract
T cells for efficacy, our model will enable study of the immunological correlates of protection for VC2 oncolytic virotherapy and oncolytic virotherapy in general. Understanding the mechanisms of efficacious oncolytic virotherapy will inform the rational design of improved oncolytic virotherapies.
Topics & Concepts
Oncolytic virusBiologyVirotherapyHerpes simplex virusImmune systemVirologyCD8ImmunotherapyImmunologyVirusContext (archaeology)Cancer researchPaleontologyVirus-based gene therapy researchCAR-T cell therapy researchHerpesvirus Infections and Treatments